OTCMKTS: $RHHBY Breakthrough Results in Metabolic Research Genentech, a member of the Roche Group, recently announced promising outcomes from their Phase II clinical trials concerning enicepatide. As the field of metabolic health continues to evolve, this dual-agonist therapeutic represents a significant step forward in addressing weight management and metabolic dysregulation. Understanding the Mechanism Enicepatide is…